发明公开
- 专利标题： ADMINISTRATION OF PIRENZEPINE, METHYL SCOPOLAMINE AND OTHER MUSCARINIC RECEPTOR ANTAGONISTS FOR TREATMENT OF LIPID METABOLISM DISORDERS
- 专利标题（中）： 哌仑西平，甲基东及其他毒蕈碱受体拮抗剂的脂质代谢紊乱的治疗管理
-
申请号： EP95927259申请日： 1995-06-20
-
公开(公告)号： EP0764026A4公开(公告)日： 1997-12-29
- 发明人: CINCOTTA ANTHONY H , MEIER ALBERT H , WILSON JOHN M
- 申请人： ERGO SCIENCE INC , UNIV LOUISIANA STATE
- 专利权人： ERGO SCIENCE INC,UNIV LOUISIANA STATE
- 当前专利权人： ERGO SCIENCE INC,UNIV LOUISIANA STATE
- 优先权： US26360794 1994-06-20
- 主分类号： A61K45/00
- IPC分类号： A61K45/00 ; A61K31/00 ; A61K31/13 ; A61K31/137 ; A61K31/15 ; A61K31/166 ; A61K31/195 ; A61K31/221 ; A61K31/35 ; A61K31/352 ; A61K31/40 ; A61K31/405 ; A61K31/435 ; A61K31/439 ; A61K31/445 ; A61K31/4515 ; A61K31/454 ; A61K31/46 ; A61K31/475 ; A61K31/48 ; A61K31/54 ; A61K31/5415 ; A61K31/55 ; A61K31/551 ; A61K31/5513 ; A61K31/695 ; A61K38/22 ; A61K45/06 ; A61P3/04 ; G01N33/74 ; A61K31/56 ; A61K31/38 ; A61K31/44 ; A61K47/00
摘要：
Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.
信息查询
